Nonaethylene Glycol Monododecyl Ether

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

Cosmetic ingredients (Laureth-9) -> CIR (Cosmetic Ingredient Review)

Emulsifying

Breast Feeding; Lactation; Milk, Human; Detergents; Sclerosing Solutions; Sclerotherapies; Surface-Active Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

FCS -> FDA Cumulative Estimated Daily Intake (CEDI)

FCS -> FDA Cumulative Estimated Daily Intake (CEDI)

FCS -> FDA Inventory of Food Contact Substances Listed in 21 CFR

FCS -> FDA Inventory of Food Contact Substances Listed in 21 CFR

Danger

H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P305+P354+P338, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 10 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

The CIR Expert Panel concluded that the alkyl PEG ethers, listed below, are safe in the present practices of use and concentration described in this safety assessment when formulated to be nonirritating. This assessment is also intended to address future alkyl PEG ether cosmetic ingredients that vary from those ingredients recited herein only by the number of ethylene glycol repeat units...Laureth-9...

Safe for use in cosmetics, with qualifications

Drug Induced Liver Injury Rank (DILIrank 2.0)

Polidocanol

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

C05BB02

C - Cardiovascular system

QC - Cardiovascular system

When administered, polidocanol locally damages blood vessel endothelium. Following the endothelial damage, platelets aggregate at the site and attach to the venous wall eventually resulting in a dense network of platelets, cellular debris, and fibrin that occludes the vessel. Eventually the vessel is replaced by connective fibrous tissue.

0AWH8BFG9A

POLIDOCANOL

Established Pharmacologic Class [EPC] - Sclerosing Agent

Mechanisms of Action [MoA] - Sclerosing Activity

Physiologic Effects [PE] - Vascular Sclerosing Activity

Polidocanol is a Sclerosing Agent. The mechanism of action of polidocanol is as a Sclerosing Activity. The physiologic effect of polidocanol is by means of Vascular Sclerosing Activity.

Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties.

Chemical agents injected into blood vessels and lymphatic sinuses to shrink or cause localized THROMBOSIS; FIBROSIS, and obliteration of the vessels. This treatment is applied in a number of conditions such as VARICOSE VEINS; HEMORRHOIDS; GASTRIC VARICES; ESOPHAGEAL VARICES; PEPTIC ULCER HEMORRHAGE.

When given intravenously, the maximum blood concentrations were reached in 15 mins.

Route of elimination was not indicated.

When given intravenously, the volume of distribution was 35-82L.

Sytemic clearance was 0.2-0.4 L/min.

CIR ingredient: Laureth-9

Use (kg; approx.) in Germany (2009): >5000